| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/14/2013 | CA2455915C Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| 05/14/2013 | CA2441562C Short bioactive peptides and methods for their use |
| 05/14/2013 | CA2435562C Carotenoids as anti-hypertension agents |
| 05/14/2013 | CA2388298C The use of csf-1 inhibitors |
| 05/14/2013 | CA2263890C Recombinant vascular endothelial cell growth factor d (vegf-d) |
| 05/14/2013 | CA2242342C Isolated dimeric fibroblast activation protein alpha, and uses thereof |
| 05/10/2013 | WO2013067162A1 Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| 05/10/2013 | WO2013067151A1 Treatment methods using diarylthiohydantoin derivatives |
| 05/10/2013 | WO2013067131A1 Treatment methods |
| 05/10/2013 | WO2013066483A1 Synergistic combinations of pi3k- and mek-inhibitors |
| 05/10/2013 | WO2013066277A1 Synergic compositions |
| 05/10/2013 | WO2013066168A1 Composition for improving neuropsychological test battery score |
| 05/10/2013 | WO2013066167A1 Method for improving executive function |
| 05/10/2013 | WO2013066165A1 Improving recognition |
| 05/10/2013 | WO2013066153A1 Composition for improving neuropsychological test battery score |
| 05/10/2013 | WO2013066152A1 Method for improving executive function |
| 05/10/2013 | WO2013066151A1 Improving recognition |
| 05/10/2013 | WO2013065690A1 Prophylactic or therapeutic agent for virus infectious disease |
| 05/10/2013 | WO2013064913A2 Method for treating type i and type ii diabetes |
| 05/10/2013 | WO2013064692A1 Triple combination for the treatment of cancer |
| 05/10/2013 | WO2013064585A1 Treatment of musculoskeletal fibroproliferative disorders |
| 05/10/2013 | CA2853971A1 Improving recognition |
| 05/10/2013 | CA2853931A1 Composition for improving neuropsychological test battery score |
| 05/10/2013 | CA2853926A1 Method for improving executive function |
| 05/10/2013 | CA2853799A1 Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| 05/10/2013 | CA2846454A1 Synergistic combinations of pi3k- and mek-inhibitors |
| 05/09/2013 | US20130116336 Treatment of ataxia telangiectasia |
| 05/09/2013 | US20130116324 Pharmaceutical composition for the prevention or treatment of inflammatory diseases or immune diseases containing ramalin |
| 05/09/2013 | US20130116323 Methods of improving or preserving lung function in a patient with a pulmonary disorder |
| 05/09/2013 | US20130116317 Furanyl compounds and the use thereof |
| 05/09/2013 | US20130116309 Oligomeric compounds for the modulation of hif-1a expression |
| 05/09/2013 | US20130116290 Use of Dipeptidyl Peptidase IV Effectors for Normalizing the Blood Glucose Level in Mammals |
| 05/09/2013 | US20130116286 Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension |
| 05/09/2013 | US20130116285 Chemical Compounds |
| 05/09/2013 | US20130116274 Therapeutic combinations containing riluzole |
| 05/09/2013 | US20130116262 Bicyclic piperazine compounds |
| 05/09/2013 | US20130116260 Fused heteroaromatic pyrrolidinones as syk inhibitors |
| 05/09/2013 | US20130116259 Combination therapy for treating or preventing an inflammatory skin disorder |
| 05/09/2013 | US20130116255 Combination of brimonidine and timolol for topical ophthalmic use |
| 05/09/2013 | US20130116250 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof |
| 05/09/2013 | US20130116249 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof |
| 05/09/2013 | US20130116247 IRE-1alpha INHIBITORS |
| 05/09/2013 | US20130116246 8-fluorophthalazin-1(2h)-one compounds |
| 05/09/2013 | US20130116245 Alkylated piperazine compounds |
| 05/09/2013 | US20130116235 Heteroaryl pyridone and aza-pyridone compounds |
| 05/09/2013 | US20130116223 Medicinal cosmetic lipoatrophy |
| 05/09/2013 | US20130116215 Combination therapies for treating neurological disorders |
| 05/09/2013 | US20130116207 Compositions and Methods for Treating Cancer |
| 05/09/2013 | US20130116206 Quinoline derivatives used as pet imaging agents |
| 05/09/2013 | US20130116171 Methods for treating metabolic disorders using fgf |
| 05/09/2013 | US20130116169 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| 05/09/2013 | US20130115314 Compounds Useful as Inhibitors of ATR Kinase |
| 05/09/2013 | US20130115265 Drug delivery system |
| 05/09/2013 | US20130115228 Immunostimulatory combinations |
| 05/09/2013 | US20130115221 HIFa prolyl hydroxylation assay |
| 05/09/2013 | US20130115206 Compositions and Methods for Treating and Diagnosing Cancer |
| 05/09/2013 | US20130115202 Anti-inflammatory compositions for treating neuro-inflammation |
| 05/09/2013 | US20130115193 Hepatitis C Virus Inhibitors |
| 05/09/2013 | US20130115191 T cell receptor fusions and conjugates and methods of use thereof |
| 05/09/2013 | US20130115181 Aqueous pharmaceutical system for the administration of drugs to the nails |
| 05/09/2013 | US20130115177 Topical compositions and methods for epithelial-related conditions |
| 05/08/2013 | EP2589386A1 Method for inhibiting myopia and use of adenylate cyclase inhibitor as drug for inhibiting myopia |
| 05/08/2013 | EP2589385A1 Triple combination for the treatment of cancer |
| 05/08/2013 | EP2588139A1 New combination treatment for type 2 diabetes and other disorders related to insulin resistance |
| 05/08/2013 | EP2588125A2 Functional vascularization with biocompatible polysaccharide-based hydrogels |
| 05/08/2013 | EP2588107A1 COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| 05/08/2013 | DE102011085862A1 Composition useful for coating surface of article, comprises antimicrobial agent, which acts as proton donor when contacted with aqueous medium, and active substance partly coated with coating material, which has lower water solubility |
| 05/08/2013 | CN103096929A Agent for treatment of dry eye characterized by combining P2Y2 receptor agonist with hyaluronic acid or salt thereof, method for treating dry eye, and use of the P2Y2 receptor agonist and hyaluronic acid or salt thereof |
| 05/08/2013 | CN103096928A Prophylactic or ameliorating agent for genetic diseases |
| 05/08/2013 | CN103096917A Trefoil factors (TFF) for the treatment of chronic pulmonary diseases |
| 05/08/2013 | CN103096897A Pharmaceutical compositions comprising R (+) budesonide and one or more bronchodilators |
| 05/08/2013 | CN103096870A Methods and compositions for modulating hair growth |
| 05/08/2013 | CN103087311A Amphipathy triblock polymer and preparation method and application thereof |
| 05/08/2013 | CN103087067A Compound serving as dipeptidyl enzyme inhibitor and composition thereof and applications of compound and composition |
| 05/08/2013 | CN103083672A DPP-IV inhibitor combined with further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
| 05/08/2013 | CN103083671A Medicine composition of tyrosine kinase inhibitor and histone deacetylase inhibitor |
| 05/08/2013 | CN103083670A Application of inhibiting agent of cathepsin K |
| 05/08/2013 | CN103083669A Method for treatment of inflammatory disease and disorder |
| 05/08/2013 | CN103083668A Protein for regulating lipid metabolism and application thereof |
| 05/08/2013 | CN103083667A Continuous dosage scheme of olfactory ensheathing cell proliferation reagent |
| 05/08/2013 | CN103083666A Drug composition, drug composition preparation and drug composition uses |
| 05/08/2013 | CN103083645A Application of neuregulin 1 and acceptor thereof as target for preparing and screening anti-epileptic drugs |
| 05/08/2013 | CN103083643A Methods for increasing absorption of peptides, peptidomimetics, and other gastrointestinal transport protein substrates |
| 05/08/2013 | CN103083285A Oral mucosa medicine slow-release preparation for treating oral and periodontal diseases by using tetracycline |
| 05/08/2013 | CN103083284A Film preparation and its preparation method |
| 05/08/2013 | CN103083223A Galactose modified sulfhydryl chitosan quaternary ammonium salt nanoparticle, as well as preparation method and application thereof |
| 05/08/2013 | CN103082399A Snuff and preparation method thereof |
| 05/08/2013 | CN102475890B Acceptor protein, and coding gene and application thereof |
| 05/08/2013 | CN102397550B Medicinal composition composed of aspirin and estrogen and used for preventing and treating osteoporosis |
| 05/08/2013 | CN102274390B Medicinal composition for high-androgen polycystic ovary syndrome |
| 05/08/2013 | CN101959516B Methods of treating by inhibiting with quinaxoline inhibitors of PI3K-alpha |
| 05/07/2013 | US8436148 Antibodies against interleukin-18 binding protein, their preparation and use |
| 05/07/2013 | US8436119 Allergen suppressor, allergen-suppression processed fiber and method of producing the same |
| 05/07/2013 | US8436010 Treatment of solid tumors with rapamycin derivatives |
| 05/07/2013 | US8435801 Methods and compositions for the production of monoclonal antibodies |
| 05/07/2013 | US8435574 Compositions for alleviating inflammation and oxidative stress in a mammal |
| 05/07/2013 | US8435533 Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of Chlamydia |
| 05/07/2013 | US8435520 Combinations of immunosuppressive agents for the treatment or prevention of graft rejections |
| 05/07/2013 | US8435503 Ophthalmic and ophthalmological use of a complex nutritive base in aqueous medium |
| 05/07/2013 | CA2558029C Ion binding polymers and uses thereof |